NextCure, Inc.
NXTC
$0.3348
$0.00210.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.35% | -19.16% | -28.63% | -19.54% | -19.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.12% | -20.00% | -13.91% | -7.67% | -11.15% |
| Operating Income | 21.12% | 20.00% | 13.91% | 7.67% | 11.15% |
| Income Before Tax | 19.80% | 19.31% | 13.75% | -6.28% | 16.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.80% | 19.31% | 13.75% | -6.28% | 16.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.80% | 19.31% | 13.75% | -6.28% | 16.38% |
| EBIT | 21.12% | 20.00% | 13.91% | 7.67% | 11.15% |
| EBITDA | 21.28% | 19.61% | 13.24% | 7.07% | 10.73% |
| EPS Basic | 20.10% | 19.70% | 14.18% | -5.80% | 16.76% |
| Normalized Basic EPS | 20.12% | 19.71% | 14.19% | 9.94% | 16.75% |
| EPS Diluted | 20.10% | 19.70% | 14.18% | -5.80% | 16.76% |
| Normalized Diluted EPS | 20.12% | 19.71% | 14.19% | 9.94% | 16.75% |
| Average Basic Shares Outstanding | 0.37% | 0.49% | 0.52% | 0.46% | 0.46% |
| Average Diluted Shares Outstanding | 0.37% | 0.49% | 0.52% | 0.46% | 0.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |